TGFB1 and cancer: Combining chemotherapeutic drugs with TGF‐β kinase inhibitors shows promise in preclinical and clinical studies, highlighting TGF‐β as a valuable cancer target and underscoring the importance of advancing understanding of its signaling pathways and refining patient selection to improve therapeutic outcomes.